HUTCHMED (China) Ltd (HCM) stock
Close on Nov 12, 2026Market cap $2.59BP/E 5.7Yield –
HUTCHMED (China) Ltd saw revenue fall 13.0% to $548.51M over fiscal 2025. Free cash flow was -$78.81M. At the latest close the market valued the company at $2.59B, 5.7 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $2.59B
- P/E ratio
- 5.7
- Price to sales
- 4.72
- Price to book
- 2.05
- Dividend yield
- –
- Free cash flow yield
- -3.04%
Fundamentals
- Revenue
- $548.51M
- Net income
- $456.91M
- EPS, diluted
- $0.52
- Free cash flow
- -$78.81M
Trading
- Previous close
- $15.08
- Open
- $14.99
- Day's range
- $14.81 – $15.00
- Volume
- 24,794
- Average volume (20 days)
- 47,803
- Beta (5 years)
- 0.97
- 52-week range
- $9.77 – $16.33
- RSI (14 days)
- 57.6
- Volatility (1 year)
- 39.8%
- Relative volume
- 0.40×
- WACC
- 9.5%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | HCM | S&P 500 | Difference | HCM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.6% | -2.7% | +11.2 pts | ||
| 3 months | +21.2% | -1.7% | +23.0 pts | ||
| Year to date | +11.4% | +11.9% | −0.5 pts | ||
| 1 year | -2.8% | +12.0% | −14.8 pts | ||
| 3 years | -21.9% | +78.2% | −100.1 pts | -7.9% | +21.2% |
| 5 years | -52.2% | +73.2% | −125.4 pts | -13.7% | +11.6% |
| 10 years | +22.7% | +309.6% | −286.9 pts | +2.1% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases HUTCHMED (China) filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About HUTCHMED (China)
Pharmaceutical Preparations
HUTCHMED (China) Limited is a commercial-stage biopharmaceutical company engaged in discovering, developing, and commercializing targeted therapies and immunotherapies. Its research and clinical development pipeline targets patients with various cancers and immunological diseases. The enterprise operates across novel oncology and immunology therapies alongside another venture focused on the marketing and distribution of prescription drugs and healthcare products. Key approved treatments include fruquintinib, savolitinib, and surufatinib, alongside licensed therapies like tazemetostat. The company distributes its medicines directly and collaborates with global pharmaceutical partners to deliver therapies to patients worldwide.
Company profile, executives and historyHUTCHMED (China) stock: common questions
What is HUTCHMED (China)'s stock price?
HCM closed at $14.85 on Nov 12, 2026, down 1.53% on the day. Over the past 52 weeks it traded between $9.77 and $16.33.
What is HUTCHMED (China)'s market cap?
HUTCHMED (China) was worth $2.59B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is HCM's P/E ratio?
HCM trades at 5.7 times earnings, based on diluted earnings per share of $0.52 over fiscal 2025.
How much revenue does HUTCHMED (China) make?
HUTCHMED (China) reported revenue of $548.51M for fiscal 2025, down 13.0% from a year earlier.
Does HUTCHMED (China) pay a dividend?
No. HUTCHMED (China) has not paid a cash dividend over the last twelve months.
How has HCM stock performed over the past year?
Including dividends, HCM returned -2.8% over the past year, against +12.0% for the S&P 500.
Who are HUTCHMED (China)'s competitors?
Companies most similar to HUTCHMED (China) by business, industry and size include AAPG, ZLAB, NUVB, NRIX, PTGX.
See a number that looks wrong?